StepStone Group’s Phathom Pharmaceuticals PHAT Stock Holding History

StepStone Group’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.69M	Hold	422,085	–	–	2.26%	9
2025 Q4	$4.97M	Hold	422,085	–	–	2.66%	8
2025 Q3	$4.97M	Hold	422,085	–	–	2.34%	7
2025 Q2	$4.05M	Hold	422,085	–	–	8.03%	5
2025 Q1	$2.65M	Hold	422,085	–	–	2.72%	7
2024 Q4	$3.43M	Hold	422,085	–	–	3%	7
2024 Q3	$7.63M	Hold	422,085	–	–	2.78%	8
2024 Q2	$4.35M	Hold	422,085	–	–	0.88%	9
2024 Q1	$4.48M	Hold	422,085	–	–	0.95%	10
2023 Q4	$3.85M	Hold	422,085	–	–	0.69%	10
2023 Q3	$4.38M	Hold	422,085	–	–	0.98%	9
2023 Q2	$6.04M	Hold	422,085	–	–	1.12%	10
2023 Q1	$3.01M	Hold	422,085	–	–	0.56%	12
2022 Q4	$4.74M	Hold	422,085	–	–	0.62%	16
2022 Q3	$4.68M	Hold	422,085	–	–	0.67%	16
2022 Q2	$3.56M	Hold	422,085	–	–	0.38%	19
2022 Q1	$5.75M	Hold	422,085	–	–	0.43%	15
2021 Q4	$8.3M	Hold	422,085	–	–	0.47%	18
2021 Q3	$13.5M	Buy	+422,085	New	+$14M	0.88%	10

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

StepStone Group's PHAT Position: Q1 2026 in Review

StepStone Group held its Phathom Pharmaceuticals (PHAT) position steady in Q1 2026 at 422,085 shares worth $4.69M. The position accounts for 2.26% of the portfolio, ranked #9.

StepStone Group first reported a position in PHAT in Q3 2021 and has held it in 19 quarters since. The position peaked at $13.5M in Q3 2021. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

StepStone Group held 422,085 shares of Phathom Pharmaceuticals worth $4.69M as of Q1 2026.
StepStone Group left its Phathom Pharmaceuticals share count unchanged in Q1 2026.
Phathom Pharmaceuticals made up 2.26% of StepStone Group's portfolio in Q1 2026, its #9 holding.
StepStone Group first reported a position in Phathom Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
StepStone Group's Phathom Pharmaceuticals position peaked at $13.5M in Q3 2021.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on StepStone Group's 13F filing for Q1 2026, filed 15 May 2026.